THE HELITRA EDIT

Tag: nearterm

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts

August 27, 2024

Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…

Healthcare

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts

August 27, 2024

Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…

Healthcare

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts

August 27, 2024

Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…